This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
Jeitler K, Semlitsch T, Nachtnebel A, von Minckwitz G. Everolimus (Afinitor® or Votubia®) in combination with exemestane in postmenopausal women with oestrogen receptor positive, HER2- negative locally advanced or metastatic breast cancer who are refractory to letrozole or anastrozole. Vienna: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBIHTA). Horizon Scanning in Oncology Nr. 32. 2012
Subject indexing assigned by CRD
Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Females; Postmenopause
Country of organisation
An English language summary is available.
Address for correspondence
Ludwig Boltzmann Institute fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7 rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99 Email: email@example.com
Date abstract record published